Novo Nordisk confident of amycretin obesity drug launch this decade
Go back to Novo Nordisk confident of amycretin obesity drug launch this decade| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 45.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $45.88 | 52 Week High | $59.00 | |||
| Open | $45.88 | 52 Week Low | $32.80 | |||
| Day High | $45.88 | P/E | N/A | |||
| Day Low | $45.88 | EPS | $0.00 | |||
| Volume | 214,558 | |||||
